- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06279403
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Upfront Toripalimab Plus Axitinib Combined With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Study Objective: To determine the efficacy of upfront immune checkpoint inhibitors combined with deferred cytoreductive nephrectomy in treating metastatic renal cell carcinoma.
Primary Endpoint: Pathological Major Response (MPR), defined as the percentage of residual tumor cells <10% in the primary tumor after nephrectomy.
Study Design:
Population: Participants meeting the diagnostic criteria with biopsy-proven clear cell renal cell carcinoma, IMDC score ≤3, or ≤5 metastatic lesions involving ≤3 organs.
Sample Size: 20 participants.
Patient Grouping: Non-randomized.
Interventions: Eligible participants will receive upfront treatment with a combination of Axitinib and Toripalimab for 4 cycles. After 2 cycles of treatment, radiological assessment will be conducted using RECIST 1.1 criteria. If disease progression is observed, the clinical trial will be terminated, and second-line treatment will be initiated according to guidelines. If disease progression is not observed, treatment will continue for 2 additional cycles followed by repeat radiological assessment before undergoing surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Voluntary consent to participate in this study and signing of an informed consent form.
Male or female participants aged ≥18 years and <80 years. Histologically diagnosed with clear cell carcinoma or predominantly clear cell renal cell carcinoma.
Clinical stage determined by CT or MRI: anyTN1M0 or anyTN0M1; IMDC score ≤3, or ≤5 metastatic lesions involving ≤3 organs; and the primary tumor (unilateral or bilateral) is resectable.
ECOG performance status: 0 or 1. No clinically significant cardiac, bone marrow, hepatic, or renal function abnormalities.
A willingness and ability to comply with testing and follow-up procedures.
Exclusion Criteria:
Non-clear cell carcinoma. Severe liver or kidney dysfunction, or other severe diseases. Immune deficiency, organ transplantation, or autoimmune diseases. Severe central nervous system diseases. Other malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin and cervical carcinoma in situ.
Unable to comply with regular follow-up visits due to psychological, social, family, or geographical reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Experimental arm
|
Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.
Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia. Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function. Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively.
Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Major Response (MPR)
Time Frame: through study completion, an average of 1 year
|
The percentage of residual tumor cells in the primary tumor after surgery, with MPR defined as less than 10% of residual tumor cells in the pathology report.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Axitinib
Other Study ID Numbers
- IIT-2023-0277
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Checkpoint Inhibitors
-
Institut BergoniéInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedCancer Treated With Immune-checkpoint InhibitorsFrance
-
Michael ScharlRecruitingCancer | Immunotherapy | Immune Checkpoint Inhibitors | Fecal Microbiota TransplantationSwitzerland
-
Centre Hospitalier Universitaire, AmiensCentral Hospital Saint QuentinRecruitingImmunotherapy | Immune Checkpoint Inhibitors | Immune-related Adverse Event | Predictive BiomarkersFrance
-
First People's Hospital of HangzhouNot yet recruitingBiliary Tract Cancer | Gemcitabine | Immune Checkpoint InhibitorsChina
-
Peking Union Medical College HospitalRecruiting
-
First Affiliated Hospital of Guangxi Medical UniversityRecruitingColonic Neoplasms | Neoadjuvant Therapy | Immune Checkpoint InhibitorsChina
-
M.D. Anderson Cancer CenterRecruitingImmune Checkpoint TherapyUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingCancer | Immune Checkpoint Inhibitors | Metabolism DisorderFrance
-
Hunan Cancer HospitalJiangsu Hengrui Pharmaceuticals Co.,LtdRecruitingHepatocellular Carcinoma | Immune Checkpoint InhibitorsChina
-
Nanjing Medical UniversityCompletedImmune Checkpoint Inhibitor | Endocrine ToxicityChina
Clinical Trials on Toripalimab
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Urothelial CarcinomaChina
-
Henan Cancer HospitalUnknownEsophageal Squamous Cell Carcinoma
-
Sun Yat-sen UniversityThe First Affiliated Hospital of Guangzhou Medical University; Guangzhou Panyu...RecruitingStudy of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent ChemoradiotherapySmall Cell Lung Cancer Limited StageChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHead and Neck Squamous Cell CarcinomasChina
-
Shanghai Junshi Bioscience Co., Ltd.Not yet recruitingMelanoma | Breast Cancer | Lung CanceChina
-
Zhejiang Genfleet Therapeutics Co., Ltd.CompletedAdvanced Solid TumorChina, Australia
-
Fudan UniversityUnknownMelanoma Stage IIIB-IVChina
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, Taiwan, Georgia, United States
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Qianfoshan HospitalRecruiting